Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666348 | 1.00 | SLC5A2 (0.51) | SLC5A2SLC5A1 | |
| SCHEMBL16457244 | 0.84 | SLC5A2 (0.59) | SLC5A2SLC5A1 | |
| SCHEMBL1039664 | 0.84 | SLC5A2 (0.59) | SLC5A2SLC5A1 | |
| SCHEMBL16457243 | 0.84 | SLC5A2 (0.59) | SLC5A2SLC5A1 | |
| SCHEMBL28823567 | 0.74 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| SCHEMBL19226959 | 0.72 | SLC5A2 (0.58) | SLC5A2SLC5A1 | |
| SCHEMBL28823577 | 0.70 | SLC5A2 (0.80) | SLC5A2SLC5A1 | |
| SCHEMBL19662122 | 0.70 | SLC5A2 (0.58) | SLC5A2SLC5A1 | |
| SCHEMBL19275060 | 0.70 | SLC5A2 (0.77) | SLC5A2SLC5A1 | |
| SCHEMBL19275084 | 0.70 | SLC5A2 (0.67) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218650-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | LEXICON PHARMACEUTICALS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20210038626-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2021-02-11 | — | — | US | disclosed |
| US-20190099436-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2019-04-04 | — | — | US | disclosed |
| US-20180311266-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | LEXICON PHARMACEUTICALS, INC. | 2018-11-01 | — | — | US | disclosed |
| US-20170087172-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2017-03-30 | — | — | US | disclosed |
| EP-2542236-B1 | COMBINATIONS COMPRISING 6-BENZYLPHENYL-2- SULFURTERAHYDROPYRAN-3,4,5-TRIOL DERIVATIVES AS INHIBITORS OF SODIUM -GLUCOSE COTRANSPORTERS 1 AND 2 FOR USE IN DIABETIC PATIENTS | LEXICON PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160296547-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | CHEN JINLING (US) | 2016-10-13 | — | — | US | disclosed |
| US-9365602-B2 | Sodium glucose co-transporter inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160022718-A1 | METHODS OF LOWERING BLOOD PRESSURE | LEXICON PHARMACEUTICALS INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20150111840-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | CHEN JINLING (US) | 2015-04-23 | — | — | US | disclosed |
| US-20110218159-A1 | METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | LEXICON PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| EP-2089361-B1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100311673-A1 | SULFANYL-TETRAHYDROPYRAN-BASED COMPOUNDS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2010-12-09 | — | — | US | disclosed |
| US-7846945-B2 | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7781577-B2 | 2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol; 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester; (2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol; antidibetic, antiobesity agents | LEXICON PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2089361-A2 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008109591-A1 | PHLORIZIN ANALOGS AS INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 | LEXICON PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-09-11 | — | — | US | disclosed |
| US-20080113922-A1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-05-15 | — | — | US | disclosed |
| WO-2008042688-A2 | PHLORIZIN ANALOGS AS INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 | LEXICON PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111840-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20080113922-A1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | SLC2A1, SLC2A2, SLC5A2 | SLC5A2 3/4885SLC5A1 8/4885 |
| US-20180311266-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20160022718-A1 | METHODS OF LOWERING BLOOD PRESSURE | APOB, SLC5A2, HMGCR | SLC5A2 2/4885SLC5A1 7/4885 |
| US-20170087172-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | SLC2A1, SLC2A4, SLC5A2 | SLC5A2 3/4885SLC5A1 5/4885 |
| US-20190099436-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | SLC2A1, SLC2A4, SLC5A2 | SLC5A2 3/4885SLC5A1 5/4885 |
| US-20100311673-A1 | SULFANYL-TETRAHYDROPYRAN-BASED COMPOUNDS AND METHODS OF THEIR USE | GPR119, FABP4, LIPC | SLC5A2 16/4885SLC5A1 48/4885 |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | SLC2A1, SLC2A2, SLC5A2 | SLC5A2 3/4885SLC5A1 8/4885 |
| US-20160296547-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20210038626-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20110218159-A1 | METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20230218650-A1 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.